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Debré, 8) Institut Pasteur, Unité de Biologie des Bactéries Pathogènes à Gram Positif and 9) CNRS ERL3526, Paris, FranceAbstractStreptococcus agalactiae (group B streptococcus (GBS)) is the leading cause of invasive infections among newborns in industrialized countries,
with two described syndromes: early-onset disease (EOD) and late-onset disease (LOD). Since the introduction in many countries of
intrapartum antibioprophylaxis (IAP), the incidence of EOD has dramatically decreased, whereas that of LOD remains unchanged. We
describe the clinical and bacteriological characteristics of 438 GBS neonatal invasive infections notiﬁed to the French National Reference
Centre for Streptococci in France from 2007 to 2012. Clinical data were retrieved from hospitalization reports or questionnaires.
Capsular type, assignment to the hypervirulent clonal complex (CC)17 and antibiotic susceptibility proﬁles were determined. One
hundred and seventy-four (39.7%) and 264 (60.3%) isolates were responsible for EOD, including death in utero, and LOD, respectively.
EOD was associated with bacteraemia (n = 103, 61%) and LOD with meningitis (n = 145, 55%). EOD was mainly due to capsular
polysaccharide (CPS) III isolates (n = 99, 57%) and CPS Ia isolates (n = 40, 23%), and CPS III isolates were responsible for 80% (n = 211)
of LOD cases. CC17 accounted for 80% (n = 121) of CPS III isolates responsible for meningitis (n = 151; total cases of meningitis, 188).
Bad outcome risk factors were low gestational age and low birthweight. LOD represents almost 60% of cases of neonatal GBS disease in
France and other countries in which IAP has been implemented. This observation reinforces the need to develop new prevention
strategies targeting CC17, which is predominant in GBS neonatal infections.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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C. Joubrel and A. Tazi contributed equally to this work.IntroductionGroup B streptococcus (Streptococcus agalactiae, GBS) is the
leading cause of invasive infections among newborns in indus-
trialized countries. Two GBS-associated syndromes are usuallyMicrobiol Infect 2015; 21: 910–916
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.05.039described in neonates, according to their age of onset: early-
onset disease (EOD) and late-onset disease (LOD). EOD,
which is mostly associated with bacteraemia, occurs in the ﬁrst
week of life (0–6 days), and results from the vertical trans-
mission of the bacterium through contaminated amniotic or
vaginal secretions of a colonized mother to her newborn during
or just before delivery [1]. LOD occurs between 1 week and 3
months of life (7–89 days), and is characterized by a high rate of
associated meningitis [1–3]. Although the route of acquisition is
still unclear, the bacterium may be acquired from the mother
or from environmental sources, with a probable intestinal orious Diseases. Published by Elsevier Ltd. All rights reserved
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antenatal vaginal culture screening performed between 34 and
38 weeks of gestational age (GA) is used to identify colonized
pregnant women who need to receive intrapartum antibiotic
prophylaxis (IAP) during labour. This widely adopted measure
resulted in a signiﬁcant decline in the incidence of EOD, from
1.8 cases/1000 live births in the early 1990s to 0.26 cases/1000
live births in 2010, in the USA as well as in France [4] (www.
invs.fr). However, no further decrease has been detected
since 2010, and IAP did not lead to any changes in LOD, whose
incidence and clinical manifestations remained unaffected.
Despite the improvement in neonatal intensive care, the overall
mortality rate for GBS neonatal infections remains at approxi-
mately 10%; furthermore, 40% of infants surviving meningitis
are left with permanent neurological sequelae [5,6].
Human GBS isolates express a capsular polysaccharide
(CPS), for which ten serotypes have been described to date (Ia,
Ib, and II– IX). Since the 1970s, CPS type III has been identiﬁed
as being strongly associated with neonatal meningitis, and is
now recognized to be responsible for a substantial proportion
of EOD cases (40%) and the majority of LOD cases (60%)
worldwide [5]. Epidemiological studies revealed that one
particular hypervirulent GBS clonal complex (CC), almost
exclusively of CPS type III and designated CC17 by multilocus
sequence typing, represented almost 70% of GBS isolates
responsible for neonatal meningitis, whereas it was detected in
<12% of adult infections and colonizations [3,7,8] (www.cnr-
strep.fr). Here, we describe the results of a 6-year epidemio-
logical survey of GBS neonatal infections in France (January
2007 to December 2012) in which the clinical and bacterio-
logical characteristics of 438 neonatal infections notiﬁed to the
French National Reference Centre for Streptococci (CNR-
Strep) were analysed.Materials and methodsClinical data collection
Clinical information was abstracted from questionnaires sent
with the GBS isolates to the CNR-Strep and/or from hospi-
talization reports. Only invasive infections i.e. GBS isolated
from a normally sterile site (blood, cerebrospinal ﬂuid (CSF),
joint, bone, synovial ﬂuid, or pleural ﬂuid) were considered.
Bacteraemia was considered to be without focus when no
source of infection could be identiﬁed. Meningitis was diag-
nosed if GBS was recovered from CSF (166 cases) or in the
presence of a cellular reaction in the CSF (>20 leukocytes/
mm3) associated with GBS bacteraemia and consistent clinical
ﬁndings (22 cases). Death in utero due to GBS was deﬁned asClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologydeath associated with fetal GBS invasive infection; in our cases,
GBS isolation from cord blood, lungs, or pericardial ﬂuid.
Bacterial isolates
GBS isolates were sent to the CNR-Strep by correspondents
located throughout the national territory on a voluntary basis.
All isolates were identiﬁed as GBS on the basis of colony
morphology, Lanceﬁeld grouping with type B antisera, and,
since 2011, by matrix-assisted laser desorption ionization time-
of-ﬂight mass spectrometry (Bruker), according to the manu-
facturer’s recommendations. Molecular CPS typing was per-
formed with a multiplex PCR assay, and CC17, composed of
the hypervirulent ST-17 clone and its single-locus and double-
locus variants as deﬁned by multilocus sequence typing and
BURST analysis (http://pubmlst.org/sagalactiae/), was detected
with real-time PCR targeting the CC17-speciﬁc hvgA gene
[9–11]. Antibiotic susceptibility testing was performed ac-
cording to the European Committee on Antimicrobial Sus-
ceptibility Testing (www.eucast.org). Antimicrobial drug
resistance genes were detected with multiplex PCR, as previ-
ously described [12].
Statistical analyses
Results are expressed as the median (minimum–maximum) for
continuous variables, and n (%) for categorical variables. The
effects of continuous covariates were studied with Student’s t-
test or the Wilcoxon test when relevant. Fisher’s exact tests
were used for categorical variables.
Predictors of in-hospital death were assessed with multi-
variate logistic regression. Factors achieving a p-value of 0.05
in the univariate analysis were included in a multivariable model.
p-Values of 0.05 were regarded as indicating a signiﬁcant
association.ResultsEpidemiology of GBS neonatal infections
A total of 438 GBS neonatal invasive infections were reported
to the CNR-Strep from January 2007 to December 2012, and
the corresponding isolates were sent for analysis. Considering
the incidence of GBS infections, this collection represents
approximately 20% of GBS neonatal invasive infections in
France during this period (www.invs.fr). The number of cases
according to the time of onset (0–89 days) is shown in Fig. 1,
and the main clinical and biological features for EOD and LOD
are summarized in Table 1; 38.6% (n = 169), 60.3% (n = 264)
and 1.1% (n = 5) of the isolates were responsible for EOD,
LOD, and death in utero, respectively. The proportions of EODand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 910–916
FIG. 1. Group B streptococcus invasive neonatal diseases notiﬁed to
the French National Reference Centre for Streptococci from 2007 to
2012. Invasive cases notiﬁed during the 6-year period are reported
according to the age at disease onset, from 0 to 89 days (n = 438). EOD,
early-onset disease (0–6 days); LOD, late-onset disease (7–89 days).
912 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIand LOD did not vary signiﬁcantly during the study period (data
not shown). Ninety-one per cent (n = 154) of EOD cases
occurred during the ﬁrst 48 h after birth (median age, 1 day;
range, 0–6 days), with a male/female ratio of 0.47. Seventy-two
per cent (n = 190) of LOD cases occurred between 14 days and
56 days (2–8 weeks) of life (median age, 30 days; range, 7–89
days), with a male/female ratio of 0.55. Sixty-one per cent
(n = 103) of EOD cases were associated with bacteraemia
without focus, 27% (n = 43) with meningitis, and 6% (n = 10)
with respiratory tract infection. Conversely, meningitis was the
most common clinical manifestation of LOD, with 56%
(n = 145) of the cases (p < 0.001), followed by bacteraemia
without focus (36%, n = 93); infections at other sites were also
observed, such as osteoarticular infections (3%, n = 8) and skin
and soft tissue infections (3%, n = 8). Two cases (1%) ofTABLE 1. Clinical and biological characteristics of group B strepto
EOD (N [ 169)
Values (range) N
Age at time of onset (days), median (range) 1 (0–6) 0
Male/female ratio 80 : 89 (0.47) 0
GBS antenatal screening, n (%) 90 (86) 6
Positive antenatal GBS screening, n (%) 24 (27) 7
IAP administration, n (%) 18 (22) 8
Neonatal colonization at birth, n (%) 93 (87) 6
Gestational age (weeks), median (range) 39 (24–42) 6
Preterm birth (<37 weeks), n (%) 27 (25) —
Birthweight (g), median (range) 3015 (600–4395) 6
Low birthweight (<2500 g), n (%) 30 (28) —
Very low birthweight (1000–1499 g), n (%) 6 (6) —
Extremely low birthweight (<1000 g), n (%) 4 (4) —
Meningitis, n (%) 43 (27) 9
Mortality, n (%) 15 (11) 2
Total CC17 cases, n (%) 74 (44) 0
CC17 meningitis, n (%) 26 (60) 0
CC, clonal complex; EOD, early-onset disease; IAP, intrapartum antibiotic prophylaxis; LOD
signiﬁcant.
Statistical analyses were performed with Student’s t-test or the Wilcoxon test for continuou
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectrecurrent invasive infection were reported. In both cases, the
ﬁrst episode consisted of EOD bacteraemia followed by re-
lapses 4 weeks and 8 weeks later, despite correct antibiotic
treatment. Mortality rates were similar for EOD (11%, n = 15)
and LOD (10.1%, n = 22).
Information concerning antenatal maternal screening was
missing for 209 cases (48%). It was performed in 84% (n = 192)
of the remaining 229 cases. GBS cultures were positive in 29%
of the cases (n = 56), and the results were similar for both
syndromes (Table 1). The percentages of women who had
received IAP (data available for 81 EOD (48%) and 97 LOD
(37%) cases), as recommended by the French National Health
Authority in cases of maternal GBS colonization and/or
complicated delivery (www.has.fr), were also similar for both
syndromes (EOD, 22%, n = 18; LOD, 25%, n = 24). However,
effective IAP (two or more injections of antibiotics, including a
ﬁrst loading dose as deﬁned by the Health Authority) was
administered to 50% of GBS-positive mothers in the EOD
group (12 of 24) and to 87% in the LOD group (28 of 32). In the
EOD group, 87% (93 of 107) of the infants were colonized at
time of birth in at least one sample (gastric ﬂuid, ear, and/or
anus), as compared with 28% (24 of 87) in the LOD group (p
<0.001) (Table 1).
GBS isolate characteristics
A capsular serotype was assigned to all isolates with the
following distribution. For EOD, types III (57%) and Ia (23%)
were predominant, followed by types V (7%), II (6%), Ib (4%), IV
(2%), VI (1%), and VIII (1%). For LOD, type III was predominant
(80%), followed by types Ia (9%), Ib (5%), V (5%), and II (1%).
This distribution did not vary during the study period (data not
shown). CC17 was found only as CPS III, and accounted forcoccus (GBS) neonatal infections
LOD (N [ 264)
A Values (range) NA p
30 (7–89) 0 —
146 : 118 (0.55) 0 NS
4 102 (82) 140 NS
9 32 (31) 162 NS
8 24 (25) 167 NS
2 24 (28) 177 <0.001
0 38 (25–41) 95 <0.001
66 (39) — 0.03
3 2900 (685–4240) 99 <0.001
62 (38) — NS
15 (9) — NS
13 (8) — —
145 (56) 5 <0.001
9 22 (10.1) 46 NS
178 (67.4) 0 <0.001
95 (66) 0 NS
, late-onset disease; NA, number of cases for which data were not available; NS, not
s covariates, and with Fisher’s exact test for categorical variables.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 910–916
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neonatal infections, and for 64% and 67% of meningitis and
LOD cases, respectively (Fig. 2). Generally, CC17 isolates were
responsible for 39% and 67% of EOD and LOD bacteraemias,
respectively, and for 61% and 66% of EOD and LOD meningitis
cases, respectively (Fig. 2a), conﬁrming that CC17 is highly
associated with LOD (p <0.001) and meningitis (p 0.02).
All 438 GBS isolates were susceptible to penicillin, amoxy-
cillin, and vancomycin. Resistance to aminoglycosides was rare,
with only seven isolates (1.6%) showing high-level resistance to
kanamycin, and one isolate showing high-level resistance to
gentamicin (Table 2). Ninety per cent (n = 399) were resistant
to tetracycline, owing to tet(M) in 99% of cases. GBS isolates
were resistant to macrolides in 16.7% of cases (n = 73).
Resistance was highly correlated with CPS type, type V strains
being commonly resistant (65%, p <0.001), and type III showing
a lower resistance frequency (11.4%, p 0.04). Resistance was
mostly due to modiﬁcations of the ribosome linked to the
presence of erm(B) (50%), erm(A) (21%), or erm(T) (1%), and in
29% of the cases to an efﬂux mechanism encoded by the genetic
determinant mef.
Risk factors and disease outcome
In order to identify risk factors for the development of LOD
and meningitis, and risk factors for mortality, a statistical anal-
ysis of clinical and biological data retrieved from hospitalization
reports was performed (Tables 1 and 3). Mean birthweight and
GA were compared, and appeared to be signiﬁcantly lower in
LOD cases than in EOD cases, with proportions of preterm
birth of 39% and 25%, respectively; both of these proportions
are higher than that in the general population (approximately0
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FIG. 2. Hypervirulent clonal complex (CC)17 and group B streptococcus (G
among GBS isolates collected for each syndrome. (b) Proportions of isolates
collected for each syndrome. EOD, early-onset disease; LOD, late-onset dise
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology6%) (Table 1) [13]. Both CC17 and low GA appeared to be
associated with LOD in univariate regression, with respective
ORs and 95% CIs of 2.66 (1.78–3.96) and 1.95 (1.14–3.32),
respectively.
In the univariate analysis, factors associated with in-hospital
mortality were: preterm birth (OR 2.61 (95% CI 1.11–6.09)
for GA below 37 weeks), low birthweight (OR 3.27 (95% CI
1.40–7.63) for birthweight of <2500 g), and meningitis (OR
2.70, 95% CI 1.23–5.89)). In neonates with meningitis, CSF
Gram stain positivity was not signiﬁcantly associated with in-
hospital mortality. The CSF leukocyte count and CSF glucose
concentration were signiﬁcantly higher in surviving infants than
in dead infants (p <0.001), whereas the CSF protein concen-
tration was lower in surviving infants (p 0.02). However, none
of these biological data appeared to be predictive of disease
outcome (Table 3). The maximum C-reactive protein level was
signiﬁcantly higher in meningitis cases than in bacteraemia cases
(median 140 mg/L vs. 83 mg/L respectively, p <0.001), but was
similar in dead and surviving infants. Leukopenia (leukocyte
blood count of <5000/mm3) was present in 30.9% of infants,
but the mortality rate was not statistically different between
these children (12% vs. 5%, p 0.11). Multivariate statistical
regression identiﬁed low birthweight as the strongest risk fac-
tor for mortality, with an adjusted OR of 1.52 (95% CI
0.97–2.07).DiscussionDuring a 6-year study period, we analysed 438 cases of GBS
neonatal invasive infections, which represent approximatelyB
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and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 910–916
TABLE 2. Resistance of the main group B streptococcus capsular polysaccharide (CPS) types to antibiotics
CPS N Kanamycin, n (%) Erythromycin, n (%) Clindamycin, n (%) Tetracycline, n (%)
Ia 62 1 (2) 13 (21) 1 (2) 59 (95)
Ib 18 1 (6) 4 (22) 4 (22) 17 (94)
II 12 0 (0) 1 (8) 1 (8) 10 (83)
III 308 4 (1.3) 35 (11.4)a 21 (6.8)a 272 (88.3)
IV 4 0 (0) 2 (50) 2 (50) 3 (75)
V 26 1 (4) 17 (65)b 17 (65)b 25 (96)
Total 430 7 (1.6) 72 (16.7) 46 (10.7) 386 (89.8)
N, number of isolates.
Statistical analysis was performed with the χ2 test.
ap <0.05.
bp <0.001.
914 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMI20% of the total number of cases according to the French
Health Surveillance Institute (Institut National de Veille Sani-
taire, InVS, www.invs.fr). The CNR-Strep collection is
composed of GBS strains sent on a voluntary basis by corre-
spondents throughout the national territory, and a selection
bias towards the more severe cases cannot be excluded.
However, the proportions of EOD and LOD described here,
respectively 39% and 60% of the cases, are very close to the
national estimations, and the clinical and bacteriological char-
acteristics are similar to what have been described elsewhere in
Europe, so we can assume that our collection reﬂects the na-
tional epidemiology of neonatal GBS diseases without major
discrepancies [5,14] (www.invs.fr).
We conﬁrm, as previously suggested, that the remaining
EOD cases are mainly due to problems encountered in patient
healthcare, either because GBS antenatal vaginal screening was
not performed, gave negative results, or because IAP could not
be administered properly [4,15]. Despite consistent missedTABLE 3. Risk factors and outcomes of group B streptococcus neo
Alive (N [ 321) Dead
Values (range) NA Value
Gestational age (weeks), median (range) 38.5 (25–42) 87 35.5 (2
<37 weeks, n (%) 73 (84.9) — 13 (15
37 weeks, n (%) 161 (93.6) — 11 (6)
Birthweight (g), median (range) 3050 (685–4395) 92 2245 (
<2500 g, n (%) 72 (82.8) — 15 (17
2500 g, n (%) 157 (94.0) — 10 (6)
Clinical manifestation — 25 —
Meningitis, n (%) 133 (85.8) — 22 (14
Bacteraemia, n (%) 163 (94.2) — 10 (6)
WBC count (/mm3), median (range) 7600 (700–46 840) 119 3600 (
<5000/mm3, n (%) 59 (88.1) — 8 (12)
5000/mm3, n (%) 121 (94.5) — 7 (5)
Neutrophil blood count (/mm3), median (range) 3695 (46–33 300) 189 1178 (
Meningeal infections (n = 188)
Leukocyte CSF count (/mm3), median (range) 860 (0–36 000) 36 378 (2
CSF proteins (g/L), median (range) 2.39 (0.06–11.60) 49 3.40 (1
CSF glucose (mmol/L), median (range) 1.23 (0-4.92) 50 0.5 (0–
CSF Gram stain — 42 —
Positive, n (%) 75 (86) — 12 (14
Negative, n (%) 16 (89) — 2 (11)
CSF, cerebrospinal ﬂuid; NA, number of cases for which data were not available; NS, not si
Statistical analyses were performed with Student’s t-test or the Wilcoxon test for continuou
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcases and a possible bias in our results, this situation seems to
be well illustrated by this study, in which: (a) maternal coloni-
zation status was not known in 14% of EOD cases; (b) vaginal
screening, when performed, gave negative results in 73% of the
cases; and (iii) IAP was administered to only 50% of GBS-
colonized women. Ultimately, in the EOD group, 22% of the
mothers received IAP, whereas 87% of the infants were found
to be GBS positive at birth. These observations raise important
issues regarding current GBS prevention strategies, and high-
light the need to improve the sensitivity of GBS screening
methods, with either rapid intrapartum tests or conventional
techniques based on bacterial cultures. In the LOD group, the
proportion of GBS-colonized mothers was similar to that in the
EOD group, but almost 90% of them received IAP, and the
proportion of infants found to be colonized at birth was much
lower than in the EOD group. As already suggested, infants
could be colonized during delivery or after birth by horizontal
spread, through care by nursing staff, or by breast-feedingnatal infections
(N [ 37)
Univariate regression:
OR (95% CI)
Multivariate regression:
adjusted OR (95% CI)s (range) NA
4–42) 13 p <0.001 p <0.001
) — 2.61 (1.11–6.09) 1.21 (0.66–1.76)
— 1 —
600–3800) 12 p <0.001 —
) — 3.27 (1.40–7.63) 1.52 (0.97–2.07)
— 1 —
5 p 0.01 —
) — 2.70 (1.23–5.89) 1.17 (0.62–1.72)
— 1 —
1100–31 020) 22 p 0.11 —
— 2.34 (0.81–6.77) —
— 1 —
160–21 749) 25 NS —
0–7400) 12 p <0.001 —
.20–15.34) 11 p 0.02 —
4.44) 11 p <0.001 —
8 NS —
) — 1.28 (0.3–6.3) —
— 1 —
gniﬁcant; WBC, white blood cell.
s covariates, and with Fisher’s exact test for categorical variables.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 910–916
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Favourable conditions such as low GA and CC17 colonization
may also contribute to LOD occurrence.
In our study, the CPS distribution of GBS isolates responsible
for neonatal diseases was very similar to that described
worldwide [5,18]. CPS type III remains highly preponderant in
EOD as well as in LOD, and is almost exclusively represented
by CC17. CC17 clone is strongly associated with neonatal in-
fections, which is now well recognized worldwide, but also with
meningitis, as it is responsible for 65% of central nervous sys-
tem infections [3,7,8,18]. Altogether, these results highlight the
fact that CC17, which possesses speciﬁc virulence traits
enhancing its invasiveness, is well adapted to neonate patho-
genesis [3,19,20].
The mortality rates of GBS neonatal infections were similar
in EOD and LOD cases, but higher in meningitis cases than in
bacteraemia cases. The CSF white cell count was signiﬁcantly
lower in dead than in surviving infants, although it did not
constitute, and nor did Gram stain positivity, a signiﬁcant bad
outcome risk factor, as proposed in other studies, probably
because of the low number of cases analysed in our collection
[13]. Other recognized risk factors for mortality, such as low
birthweight and prematurity, were also identiﬁed here [2,21].
Owing to the limited amount of data, we could not investigate
elements such as ethnic group or maternal human immuno-
deﬁciency virus infection, but prematurity appeared to be the
major GBS neonatal infection risk factor, and was even more
important for LOD than for EOD [2,4,22]. Both immaturity of
the immune system and defects in the phagocytic and the
complement activities are proposed explanations for the
increased susceptibility of preterm infants to pathogenic bac-
teria. Also, the potential protection conferred by maternal anti-
GBS antibodies might be low before 34 weeks of GA, as
transplacental transmission of immunoglobulins is not yet
optimal [23].ConclusionDespite the prevention policies implemented worldwide, GBS
remains the leading cause of severe neonatal infections, notably
because of the persistence of LOD, which is highly associated
with meningitis and is caused by CC17. Considering the global
burden of GBS neonatal diseases and the limitations of universal
screening and IAP, prevention strategies need to be improved,
including vaccine development, but also accurate diagnostic
tools for more rapid, easy and sensitive screening of GBS
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